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Abstract
The development and application of Artificial Intelligence to Radiology requires an approach which 
encompasses a health system. Key elements of this approach, which are of global relevance, are 
described in the light of recent initiatives by UK government. A network of academic centres focusing 
on developing AI in radiology and digital pathology has been created with industrial partnerships 
within the NHS and the research infrastructure of the UK National Institute of Health Research (NIHR). 
Close collaboration is required between academic researchers, clinicians, industry, government 
agencies, healthcare professionals and patients to develop solutions that are safe, effective and 
integrate into clinical workflows with multidisciplinary training to ensure an upskilled workforce. The 
NHS has large archives of processed digital images acquired in relatively uniform standards but 
optimised homogeneous annotated datasets are relatively infrequent. However by using larger 
quantities of images the AI algorithms can be adapted to this more “messy” data and is arguably more 
useful as this reflects real life radiological practice. Rigorous clinical validation of these technologies 
requires thoughtful approaches as some AI tools triaging workflow are low risk compared to those 
creating a diagnostic decision support application. The EU General Data Protection Regulation (GDPR) 
has clarified the requirements for organisations that gather and process personal data and the AI field 
would benefit from international data sharing agreements. Transparency and building public trust is 
important for ensuring acceptability of implementation of these AI tools into our healthcare systems. 
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The development of ever more sophisticated imaging technologies, such as computerised 
tomography (CT), different forms of Magnetic Resonance Imaging (MRI), Positron Emission 
Tomography (PET) and digital pathology, has led to a significant increase in the amount of data 
generated per patient[1]. At the same time, healthcare systems around the world are struggling to 
integrate and analyse this wealth of information, due to a shortage of trained radiologists and 
pathologists and the sheer size and complexity of the datasets available. 
Academia and industry are focusing on developing artificial intelligence (AI) techniques – 
encompassing machine learning (ML) and deep learning (DL) in particular – for analysing, 
interpreting, categorising and annotating clinical images. Progress in AI imaging technology is being 
driven by the rapidly expanding processing power of GPUs, falling costs of computing and data 
storage, the availability of large datasets for training and significant financial input from private and 
commercial investors and government sources. 
For example, in November 2018, the UK Government announced funding of just under £50 million 
(~$65 million) for a network of academic centres focusing on developing AI in radiology and digital 
pathology. A further £33 million (~$42 million) in funding has been leveraged from universities, 
charities and companies ranging from small start-ups to major commercial players. Furthermore, the 
UK National Institute of Health Research (NIHR) is probably the world's largest integrated health 
research system, with more than £500m pa of research infrastructure embedded in the NHS, 
designed to deliver high quality research at pace, in partnership with patients, industry, charities and 
UK Research & Innovation (UKRI). Working with the devolved nations, the NIHR is evolving in order 
to ensure the UK health system is well-placed to deliver high quality studies of AI in imaging.
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However, while AI has the potential to transform clinical imaging practice around the world by 
improving productivity and performance, there are significant issues that need to be resolved before 
it is adopted in clinical practice at scale. Although our focus is on the UK landscape, the challenges 
we face are relevant to the international research community of academic, clinical and industry 
partners working to speed the translation of AI imaging technologies into routine clinical practice. 
Creating an ecosystem
Bringing the power of AI to bear on clinical imaging is a multidisciplinary effort, requiring close 
collaboration between academic researchers, clinicians, industry, government agencies, healthcare 
professionals and patients to develop solutions that are safe, effective and integrate into clinical 
workflows. Engineering these partnerships and creating a research ecosystem in which they can 
flourish will rely on strategic direction and investment from national bodies, including government-
funded research organisations, industry and professional societies. The need to pivot towards ever-
increasing automation and AI technology in healthcare is particularly pressing in countries like 
Singapore, where an ageing population and restrictions on non-native workers are putting pressure 
on services.
While much of the attention in AI is focused on data and algorithm development, it is essential to 
remember the importance of skilled scientists and clinicians. This requires investment in 
multidisciplinary training programmes spanning the entire career pathway from studentships to 
fellowships and beyond, covering both clinical and non-clinical researchers. More should be done to 
encourage cross-disciplinary talent transfer, not just for medical doctors moving into AI research but 
also bringing physicists, mathematicians, engineers and computer scientists into closer proximity 
with biomedical researchers. This could extend to cross-disciplinary degrees, fellowships or even 
clinical placements to encourage people with AI skills to move into medical imaging. 
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One important issue to be considered is the financial incentives available. Given that AI-based 
companies can offer significantly higher salaries than those available for academic researchers, 
developing effective partnerships with industry will be an important means of developing and 
retaining talent as the field grows. In the UK, UKRI and the NIHR now have a range of fellowship 
programmes which encourage cross-disciplinary working and industry placements. 
There is a risk that recruitment into training programmes will be hampered by misplaced concerns 
that radiology and pathology will become redundant thanks to the advent of AI technologies, further 
depressing these disciplines that are already struggling. Instead, we must focus on promoting the 
model of the ‘centaur’ – a highly trained human working together with an AI to achieve more than 
would be possible alone. We should remember the lessons learned from the introduction of 
spreadsheets in the late 1970s: fears that this new software would completely remove the need for 
accountants couldn’t have turned out to be further from the truth. Instead, by removing the 
drudgery of basic tasks, the technology revolutionised the profession by freeing up human brains to 
focus on tasks for which they are better equipped. 
Building a pipeline for development and validation
There are two main challenges to be overcome when bringing AI techniques into clinical imaging: 
development of the tools themselves and their subsequent clinical validation and approval. These 
two strands must run in parallel and be closely intertwined – there is no point developing an 
impressive algorithm if it cannot be integrated into day-to-day service delivery, demonstrate its 
effectiveness and utility in real life situations and meet the conditions for regulatory approval. 
Furthermore, any AI-based imaging system must fit seamlessly into established clinical workflows – 
for example, integrating into existing workstations rather than operating in a standalone unit – 
otherwise it is unlikely to be widely adopted. It also has to demonstrate increased productivity, 
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better patient outcomes and cost effectiveness, particularly in settings with stretched healthcare 
budgets. 
The most significant limiting factor in the development of AI technologies is the availability of 
sufficiently large, good quality training data. Keeping images in the AI pipeline is crucial for human 
interpretation and validation of resulting algorithms. Ideally, datasets should be uniformly acquired 
with standardised protocols across all sources, consistently annotated and anonymised or pseudo-
anonymised, depending on where and how they will be used. Annotation currently requires human 
input, creating a bottleneck in the process due to the lack of trained radiologists and pathologists. 
This is driving the trend towards unsupervised learning techniques – where salient features are 
recognised without human intervention – as well as the use of computer-generated training data 
created through generative adversarial networks. 
There is also a shift away from using training data comprising processed images that are optimised 
for human viewing only and towards integrating raw acquisition data and physics models of the 
acquisition into the AI workflow. This would allow the creation of homogenised image datasets and 
their direct optimisation for diagnosis and treatment planning. There are also issues around 
interoperability and regional variations; an algorithm that works with data generated on one make 
of machine may not perform as well with images gathered from another.  
Despite the enthusiasm for developing AI-based imaging tools, rigorous clinical validation of these 
technologies remains a major challenge [2]. Unlike pharmaceutical companies, which must navigate 
a highly complex and well-established regulatory environment in order to gain approval for novel 
therapies, the regulatory framework for AI-based clinical technologies is still playing catch-up. Any 
validation test should be appropriate to the level of risk involved. For example, an algorithm 
designed to triage patients in a fracture clinic can tolerate more error than one designed to assess 
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correct placement of a nasogastric feeding tube, where the outcomes of misplacement are life-
threatening. Therefore, there is a critical need for the development of robustness measures and 
uncertainty quantification for AI techniques and their requirements in varying clinical settings.
Local differences in practice and patient populations also pose challenges; will a tool that has been 
developed using a population of breast cancer patients in Scotland be relevant to women in the 
southern states of the USA, or even in the south of England? Training and test datasets therefore 
need to be truly representative of the patient population to which the algorithm will be applied, or 
the specific patient population should be specified as part of the regulatory process. It is possible to 
imagine a solution for DL technologies where there is a core algorithm with ‘add-ons’ allowing for 
domain adaptation and consequently account for these local variations.
Replication and reproducibility are significant concerns for clinical validation, particularly for results 
produced by proprietary algorithms generated by commercial organisations that are reluctant to 
reveal their ‘special sauce’. The benchmark for all AI imaging technologies should therefore be 
published, peer reviewed clinical trials, with as much transparency around the methodology, 
algorithm, training and test datasets and possible sources of bias as possible. There should also be 
an accurate characterisation of failure cases: it is just as important to understand any ‘blind spots’ as 
it is to demonstrate an impressive detection rate. 
As more AI-based platforms come to market, a concerted effort needs to be put into establishing 
standardised independent test datasets to demonstrate accuracy, sensitivity and specificity, 
analogous to the validation and quality control panels that are available for molecular diagnostics. 
These must be large enough to avoid the problem of ‘learning to the test’ or overfitting and allow for 
frequent retesting.
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While it is important that any regulatory processes do not create an unnecessary barrier to clinical 
use, it is vital that there is sufficient oversight to ensure that AI technologies are safe, effective and 
accepted by patients and the public. ML/DL software is likely to fall under the banner of ‘medical 
devices’ and will therefore be subject to having to gain CE accreditation in Europe or FDA approval in 
the US, which brings a requirement for post-marketing surveillance. It is also necessary to consider 
regular retesting and revalidation of AI-based algorithms. Several new AI tools have gained CE marks 
and FDA approval based on scant and often unpublished clinical data, and there are concerns that a 
failure to properly validate and monitor the application of these technologies in the real world could 
lead to potentially serious errors, risking the loss of public and professional trust.
Data governance
Patient-derived data lies at the heart of any AI-based imaging system and is therefore subject to 
informed consent, national legal and regulatory frameworks, and societal norms. The introduction of 
the EU General Data Protection Regulation (GDPR) has clarified the requirements for organisations 
that gather and process personal data and, in our view, has been an enabler of research. However, 
there is still much confusion among the research community about how to navigate through the 
regulatory process – particularly for small commercial organisations – and further advice from 
regulatory bodies such as the UK Health Research Authority (HRA) would be welcome. There would 
also be value in the development of standardised national and international data-sharing 
agreements and contracts, which are already becoming common in pharmaceutical drug 
development and trials. 
AI research in medical imaging would benefit from new models for data accessibility, moving from 
the idea of data sharing to one of data access. Several academic and commercial organisations have 
accumulated extremely large datasets that could be of great use to the research community, and we 
would all benefit from the development of platforms that allow researchers to come and use 
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cleaned, curated data within an organisational firewall with the appropriate permissions. This would 
have the advantage of democratising data science, reducing barriers to entry for small organisations 
and countries with less investment in their health data infrastructure.
Public trust
Patients should be at the heart of research, not only as beneficiaries of these new technologies but 
also as partners and participants at all stages of the process from design to delivery – a principle that 
lies at the heart of the NIHR. As well as being ethically correct, patient and public engagement and 
involvement makes research more effective, encouraging trial participation and retention and 
ensuring that the results of research are more likely to bring meaningful benefits. Despite recent 
high-profile scandals around the mis-use and leakage of personal data, the UK public remains 
broadly supportive of the use of patient data for medical research, even by commercial 
organisations [3]. However, levels of public trust are likely to vary by country and are currently being 
investigated through programmes such as the Wellcome Trust Global Monitor [4]. 
However, just as what was acceptable practice in medical research fifty years ago is looked upon 
with horror today, we should be mindful that attitudes can change over time. There is a growing 
public suspicion of large privately-owned technology companies that gather and control personal 
data, whose priorities ultimately lie with their owners or shareholders rather than patients and the 
public, and the AI research community should continue to actively engage with patients and the 
public to monitor their concerns. For example, it is currently accepted that patients should not 
receive financial reimbursement for the use of their data or a share of the profit from any 
commercial product derived from it. That may change with the advent of blockchain technologies 
allowing individuals to control access to their personal data or even monetise it, as we are starting to 
see in the field of genomics, which are likely to impact upon public trust [5].
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Finally, academic and industry researchers should consider how to deliver effective communication 
about AI-based technologies to patients, public and health professionals. It may not be necessary to 
completely explain the ‘black box’ of each algorithm – after all, we do not expect doctors or patients 
to know the precise biological mode of action of every drug – but efforts need to be made to show 
how these tools work, the data that they are derived from, and their benefits and limitations. 
Building a culture of transparency and public understanding around the use of AI in medical imaging 
will help to secure trust and confidence in this exciting field as it moves into the future. 
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